BioCentury | Dec 14, 2018
Company News

As Medicines Co. seeks funding, Denner brings in new CEO

..."Medicines Co. Board Could Tilt Toward Denner's Control" ). Denner is chief investment officer of Sarissa Capital Management...
BioCentury | Dec 11, 2018
Company News

As Medicines Co. seeks funding, Denner brings in new CEO

..."Medicines Co. Board Could Tilt Toward Denner's Control" ). Denner is chief investment officer of Sarissa Capital Management...
BioCentury | Aug 24, 2018
Finance

Navigating the Hot Topics landscape

...Investments Adelene Q. Perkins, Chair and CEO, Infinity Pharmaceuticals Inc. Simos Simeonidis, Ph.D., Senior Analyst, Sarissa Capital Management...
BioCentury | Jun 1, 2018
Company News

Ironwood shareholders vote to keep board intact

...holds about a 2.2% stake in Ironwood and is chief investment officer at activist firm Sarissa Capital Management...
BioCentury | May 31, 2018
Company News

Ironwood shareholders opt to keep board intact

...holds about a 2.2% stake in Ironwood and is chief investment officer at activist firm Sarissa Capital Management...
BioCentury | Apr 10, 2018
Company News

Denner seeking Ironwood board seat

...Gastrointestinal disease company Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said Sarissa Capital Management LP will nominate Alex Denner for election...
BioCentury | Mar 2, 2018
Company News

Medicines Co. board could tilt toward Denner’s control

...date for the meeting has yet to be disclosed. Denner is chief investment officer of Sarissa Capital Management...
BioCentury | Mar 2, 2017
Company News

Icahn hires Mulligan as portfolio manager

...Icahn on multiple biotech boards, including Biogen Inc. (NASDAQ:BIIB). He was a founding partner of Sarissa Capital Management...
BioCentury | Jun 20, 2016
Financial News

QLT proposes private placement

...Broadfin Capital; Healthcare Value Capital; JW Asset Management LLC ; K2 & Associates Investment Management; Sarissa Capital Management...
BioCentury | Mar 7, 2016
Financial News

Apricus Biosciences completes direct public offering

...offering Raised: $7.8 million Shares: 8.8 million Price: $0.88 Shares after offering: 61.8 million Investors: Sarissa Capital Management...
Items per page:
1 - 10 of 35
BioCentury | Dec 14, 2018
Company News

As Medicines Co. seeks funding, Denner brings in new CEO

..."Medicines Co. Board Could Tilt Toward Denner's Control" ). Denner is chief investment officer of Sarissa Capital Management...
BioCentury | Dec 11, 2018
Company News

As Medicines Co. seeks funding, Denner brings in new CEO

..."Medicines Co. Board Could Tilt Toward Denner's Control" ). Denner is chief investment officer of Sarissa Capital Management...
BioCentury | Aug 24, 2018
Finance

Navigating the Hot Topics landscape

...Investments Adelene Q. Perkins, Chair and CEO, Infinity Pharmaceuticals Inc. Simos Simeonidis, Ph.D., Senior Analyst, Sarissa Capital Management...
BioCentury | Jun 1, 2018
Company News

Ironwood shareholders vote to keep board intact

...holds about a 2.2% stake in Ironwood and is chief investment officer at activist firm Sarissa Capital Management...
BioCentury | May 31, 2018
Company News

Ironwood shareholders opt to keep board intact

...holds about a 2.2% stake in Ironwood and is chief investment officer at activist firm Sarissa Capital Management...
BioCentury | Apr 10, 2018
Company News

Denner seeking Ironwood board seat

...Gastrointestinal disease company Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said Sarissa Capital Management LP will nominate Alex Denner for election...
BioCentury | Mar 2, 2018
Company News

Medicines Co. board could tilt toward Denner’s control

...date for the meeting has yet to be disclosed. Denner is chief investment officer of Sarissa Capital Management...
BioCentury | Mar 2, 2017
Company News

Icahn hires Mulligan as portfolio manager

...Icahn on multiple biotech boards, including Biogen Inc. (NASDAQ:BIIB). He was a founding partner of Sarissa Capital Management...
BioCentury | Jun 20, 2016
Financial News

QLT proposes private placement

...Broadfin Capital; Healthcare Value Capital; JW Asset Management LLC ; K2 & Associates Investment Management; Sarissa Capital Management...
BioCentury | Mar 7, 2016
Financial News

Apricus Biosciences completes direct public offering

...offering Raised: $7.8 million Shares: 8.8 million Price: $0.88 Shares after offering: 61.8 million Investors: Sarissa Capital Management...
Items per page:
1 - 10 of 35